Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) has received a consensus rating of “Buy” from the eight ratings firms that are covering the firm. One analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $43.00.

A number of equities research analysts have weighed in on the company. BTIG Research reaffirmed a “buy” rating and issued a $45.00 target price on shares of Paratek Pharmaceuticals in a report on Friday, June 17th. Robert W. Baird reiterated an “outperform” rating and issued a $40.00 price target (up from $30.00) on shares of Paratek Pharmaceuticals in a research note on Friday, June 17th. HC Wainwright increased their price target on Paratek Pharmaceuticals from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, June 17th. Cantor Fitzgerald reiterated a “buy” rating and issued a $30.00 price target (up from $27.00) on shares of Paratek Pharmaceuticals in a research note on Friday, June 17th. Finally, Ladenburg Thalmann increased their price target on Paratek Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, June 17th.

In related news, CEO Michael Bigham bought 20,000 shares of the stock in a transaction that occurred on Thursday, June 23rd. The stock was acquired at an average cost of $13.45 per share, with a total value of $269,000.00. Following the transaction, the chief executive officer now directly owns 100,000 shares in the company, valued at $1,345,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Fund Iv L.P. Omega bought 461,538 shares of the stock in a transaction that occurred on Monday, June 27th. The shares were bought at an average cost of $13.00 per share, with a total value of $5,999,994.00. The disclosure for this purchase can be found here. Corporate insiders own 2.00% of the company’s stock.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/paratek-pharmaceuticals-inc-nasdaqprtk-given-consensus-rating-of-buy-by-brokerages.html

A number of hedge funds and other institutional investors have recently made changes to their positions in PRTK. Turner Investments L.P. bought a new position in shares of Paratek Pharmaceuticals during the second quarter valued at about $883,000. Omega Fund Management LLC increased its stake in shares of Paratek Pharmaceuticals by 21.6% in the second quarter. Omega Fund Management LLC now owns 2,600,410 shares of the specialty pharmaceutical company’s stock worth $36,172,000 after buying an additional 461,538 shares during the last quarter. Swiss National Bank increased its stake in shares of Paratek Pharmaceuticals by 35.7% in the second quarter. Swiss National Bank now owns 20,900 shares of the specialty pharmaceutical company’s stock worth $291,000 after buying an additional 5,500 shares during the last quarter. Monashee Investment Management LLC acquired a new stake in shares of Paratek Pharmaceuticals during the second quarter worth $1,391,000. Finally, General American Investors Co. Inc. increased its stake in shares of Paratek Pharmaceuticals by 72.2% in the second quarter. General American Investors Co. Inc. now owns 477,076 shares of the specialty pharmaceutical company’s stock worth $6,636,000 after buying an additional 200,000 shares during the last quarter. 77.18% of the stock is owned by institutional investors and hedge funds.

Paratek Pharmaceuticals (NASDAQ:PRTK) traded up 0.80% on Tuesday, reaching $13.90. The company’s stock had a trading volume of 53,736 shares. The stock’s market cap is $314.52 million. The firm’s 50-day moving average price is $13.25 and its 200-day moving average price is $14.25. Paratek Pharmaceuticals has a 52-week low of $12.05 and a 52-week high of $27.41.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($1.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.03.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

5 Day Chart for NASDAQ:PRTK

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.